
On-field evaluation of exdia COVID-19 antigen point-of-care testing in the emergency department during the COVID-19 pandemic
Original article In Young Yoo1, Gun Dong Lee1, Hyojin Chae1, Chun Song Youn2, Eun-Jee Oh1, Yeon-Joon Park1 Department of 1Laboratory Medicine, 2Emergency Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea Corresponding to Yeon-Joon Park, E-mail: yjpk@catholic.ac.kr Ann Clin Microbiol 2022;25(3):73-78. https://doi.org/10.5145/ACM.2022.25.3.2Received on 25 January 2022, Revised on 1 May 2022, Accepted on 17 May 2022, Published on 20 September 2022.Copyright © Korean Society of Clinical Microbiology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: We evaluated the diagnostic performance of the Exdia COVID-19 antigen test (Exdia Ag; Precision Biosensor Inc., Korea) as a point-of-care (POC) test performed in the emergency department (ED) for the rapid detection of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in

